Polar Capital Holdings PLC Viridian Therapeutics, Inc.\De Transaction History

Polar Capital Holdings PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.09 - $23.82 $1.55 Million - $2.16 Million	-90,719 Reduced 9.26%	889,198 $15.6 Million
Q4 2023 Feb 14, 2024	SELL	$11.12 - $22.5 $6.9 Million - $14 Million	-620,083 Reduced 38.76%	979,917 $21.3 Million
Q2 2023 Dec 13, 2023	BUY	$22.57 - $29.67 $23.7 Million - $31.2 Million	1,050,000 Added 190.91%	1,600,000 $38.1 Million
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $23.7 Million - $31.2 Million	1,050,000 Added 190.91%	1,600,000 $38.1 Million
Q1 2023 Dec 13, 2023	SELL	$25.04 - $37.6 $26.3 Million - $39.5 Million	-1,050,000 Reduced 65.63%	550,000 $14 Million
Q1 2023 May 15, 2023	BUY	$25.04 - $37.6 $13.8 Million - $20.7 Million	550,000 New	550,000 $14 Million

181

76.7M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $795M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Polar Capital Holdings PLC with notifications on news.